Roles of prohibitin in growth control and tumor suppression in human cancers

Translational Oncogenomics

Volumn 2008, Issue 3, 2008, Pages 23-37

  Wang, Sheng ^a   Faller, Douglas V ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANTIANDROGEN; ANTIESTROGEN; CALCITRIOL; ESTROGEN RECEPTOR; PROHIBITIN; PROTEIN P53; RETINOBLASTOMA PROTEIN; TAMOXIFEN; TRANSCRIPTION FACTOR E2F; TUMOR SUPPRESSOR PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CONTROL; CANCER INHIBITION; CANCER RESEARCH; CARCINOGENESIS; CELL CYCLE REGULATION; CELL PROLIFERATION; HUMAN; MUTATIONAL ANALYSIS; PROSTATE CANCER; PROTEIN FUNCTION; PROTO ONCOGENE; TRANSCRIPTION REGULATION;

EID: 77953459457     PISSN: None     EISSN: 11772727     Source Type: Journal    
DOI: None     Document Type: Article

References (155)

1. Adler, A.J. 2007. Mechanisms of T cell tolerance and suppression in cancer mediated by tumor-associated antigens and hormones. Curr. Cancer Drug Targets, 7:3-14.
2. Agarwal, R., Agarwal, C., Ichikawa, H., Singh, R.P. and Aggarwal, B.B. 2006. Anticancer potential of silymarin: from bench to bed side. Anticancer Res., 26:4457-98.
3. Ahn, C.S., Lee, J.H., Reum Hwang, A., Kim, W.T. and Pai, H.S. 2006. Prohibitin is involved in mitochondrial biogenesis in plants. Plant J., 46:658-67.
4. Ali, S. and Coombes, R.C. 2002. Endocrine-responsive breast cancer and strategies for combating resistance. Nat. Rev. Cancer, 2:101-12.
5. Ao, M., Franco, O.E., Park, D., Raman, D., Williams, K. and Hayward, S.W. 2007. Cross-talk between paracrine-acting cytokine and chemokine pathways promotes malignancy in benign human prostatic epithelium. Cancer Res., 67:4244-53.
6. Aragon-Ching, J.B.,.Williams, K.M. and Gulley, J.L. 2007. Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer. Front Biosci., 12:4957-71.
7. Ariazi, E.A., Ariazi, J.L., Cordera, F. and Jordan, V.C. 2006. Estrogen receptors as therapeutic targets in breast cancer. Curr. Top Med. Chem., 6:195-216.
8. Battaglioli, E., Andres, M.E., Rose, D.W., Chenoweth, J.G., Rosenfeld, M.G., Anderson, M.E. and Mandel, G. 2002. REST repression of neuronal genes requires components of the hSWI.SNF complex. J. Biol. Chem., 277:41038-45.
9. Berk, A.J. 2005. Recent lessons in gene expression, cell cycle control, and cell biology from adenovirus. Oncogene, 24:7673-85.
10. Bitter, G.A. 2007. Regulation of human estrogen receptor alpha-mediated gene transactivation in Saccharomyces cerevisiae by human coactivator and corepressor proteins. J. Steroid Biochem. Mol. Biol., 103:189-95.
11. Boccardo, F., Rubagotti, A., Puntoni, M., Guglielmini, P., Amoroso, D., Fini, A., Paladini, G., Mesiti, M., Romeo, D., Rinaldini, M., Scali, S., Porpiglia, M., Benedetto, C., Restuccia, N., Buzzi, F., Franchi, R., Massidda, B., Distante, V., Amadori, D. and Sismondi, P. 2005. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J. Clin. Oncol., 23:5138-47.
12. Bostwick, D.G. and Meiers, I. 2007. Diagnosis of prostatic carcinoma after therapy. Arch. Pathol. Lab Med., 131:360-71.
13. Chiarugi, V., Magnelli, L. and Cinelli, M. 1997. Complex interplay among apoptosis factors: RB, p53, E2F, TGF-beta, cell cycle inhibitors and the bcl2 gene family. Pharmacol. Res., 35:257-61.
14. Chowdhury, I., Xu, W., Stiles, J.K., Zeleznik, A., Yao, X., Matthews, R., Thomas, K. and Thompson, W.E. 2007. Apoptosis of rat granulosa cells after staurosporine and serum withdrawal is suppressed by adenovirus-directed overexpression of prohibitin. Endocrinology, 148:206-17.
15. Cummings, B.S. 2007. Phospholipase A(2) as targets for anti-cancer drugs. Biochem. Pharmacol.,
16. Cuzick, J., Forbes, J.F. and Howell, A. 2006. Re: Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J. Natl. Cancer Inst., 98, 643; author reply 643-4.
17. Dannenberg, J.H. and te Riele, H.P. 2006. The retinoblastoma gene family in cell cycle regulation and suppression of tumorigenesis. Results Probl. Cell. Differ., 42:183-225.
18. Dasgupta, P., Padmanabhan, J. and Chellappan, S. 2006. Rb function in the apoptosis and senescence of non-neuronal and neuronal cells: role in oncogenesis. Curr Mol. Med., 6:719-29.
19. Dasgupta, P., Sun,.J., Wang, S., Fusaro, G., Betts, V., Padmanabhan, J., Sebti, S.M. and Chellappan, S.P. 2004. Disruption of the Rb - Raf-1 interaction inhibits tumor growth and angrogenesis. Mol. Cell. Biol., 24:9527-41.
20. Dehm, S.M. and Tindall, D.J. 2007. Androgen Receptor Structural and Functional Elements: Role and Regulation in Prostate Cancer. Mol. Endocrinol.,
21. Delage-Mourroux, R., Martini, P.G., Choi, I., Kraichely, D.M., Hoeksema, J. and Katzenellenbogen, B.S. 20001. Analysis of estrogen recotor interaction with a repressor of estrogen receptor activity (REA) and the regulation of estrogen receptor transcriptional activity by REA. J. Biol. Chem., 275:35848-56.
22. Delston, R.B. and Harbour, J.W. 2006. Rb at the interface between cell cycle and apoptotic decisions. Curr Mol. Med., 6:713-8.
23. Dhillon, A.S., Hagan, S., Rath, O. and Kolch, W. 2007. MAP kinase signalling pathways in cancer. Oncogene, 26:3279-90.
24. Ding, G.F., Li, J.C. and Xu, Y.F. 2006a. [Study on the correlationship between the expression of nm23H1mRNA, TGF-beta1mRNA and tumor metastases, survival rate with prostate cancer]. Fen Zi Xi Bao Sheng Wu Xue Bao, 39:544-52.
25. Ding, X.G., Li, S.W., Zheng, X.M. and Hu, L.Q. 2006b. [IFN-gamma and TGF-beta1, levels in the expressed prostatic secretions of patients with chronic abacterial prostatitis]. Zhonghua Nan Ke Xue, 12:982-4.
26. DiRenzo, J., Shang, Y., Phelan, M., Sif, S., Myers, M., Kingston, R. and Brown, M. 2000. BRG-1 is recruited to estrogen-responsive promoters and cooperates with factors involved in histone acetylation. Mol. Cell. Biol., 20:7541-9.
27. Du, W. and Pogoriler, J. 2006. Retinoblastoma family genes. Oncogene, 25:5190-200.
28. Dudderidge, T., Payne, H. and Emberton, M. 2007. An algorithm for managing the failure of external beam radiotherapy in prostate cancer. BJU Int.,
29. Duh, J.L., Yu, R., Jiao, J.J., Matwyshyn, G.A., Li, W., Tan, T.H. and Kong, A.N. 1997. Activation of signal transduction kinases by tamoxifen. Pharm. Res., 14:186-9.
30. Dunaief, J.L., Strober, B.E., Guha, S., Khavari, P.A., Alin, K., Luban, J., Begemann, M., Crabtree, G.R. and Goff, S.P. 1994. The retinoblastoma protein and BRG1 form a complex and cooperate to induce cell cycle arrest. Cell., 79:119-30.
31. El-Mowafy, A.M. and White, R.E. 1999. Resveratrol inhibits MAPK activity and nuclear translocation in coronary artery smooth muscle: reversal of endothelin-1 stimulatory effects. FEBS Lett., 451:63-7.
32. Ellis, M. 2004. Overcoming endocrine therapy resistance by signal transduction inhibition. Oncologist, 9(Suppl 3):20-6.
33. Emberton, M., Zinner, N., Michel, M.C., Gittelman, M., Chung, M.K. and Madersbacher, S. 2007. Managing the progression of lower urinary tract symptoms/benign prostatic hyperplasia: therapeutic options for the man at risk. BJU Int., 100:249-53.
34. Eveleth, D.D.Jr, and Marsh, J.L. 1986. Sequence and expression of the Cc gene, a member of the dopa decarboxylase gene cluster of Drosophila: possible translational regulation. Nucleic Acids Res., 14:6169-83.
35. Fleshner, N., Keane, T.E., Lawton, C.A., Mulders, P.F., Payne, H., Taneja, S.S. and Morris, T. 2007. Adjuvant androgen deprivation therapy augments cure and long-term cancer control in men with poor prognosis, nonmetastatic prostate cancer. Prostate Cancer Prostatic Dis.,
36. Freedland, S.J. and Moul, J.W. 2007. Prostate specific antigen recurrence after definitive therapy. J. Urol., 177:1985-91.
37. Fryer, C.J. and Archer, T.K. 1998. Chromatin remodelling by the glucocorticoid receptor requires the BRG1 complex. Nature, 393:88-91.
38. Funayama, R. and Ishikawa, F. 2007. Cellular senescence and chromatin structure. Chromosoma,
39. Fusaro, G., Dasgupta, P., Rastogi, S., Joshi, B. and Chellappan, S. 2003. Prohibitin induces the transcriptional activity of p53 and is exported from the nucleus upon apoptotic signaling. J. Biol. Chem., 278:47853-61.
40. Fusaro, G., Wang, S. and Chellappan, S. 2002. Differential regulation of Rb family proteins and prohibitin during camptothecin-induced apoptosis. Oncogene, 21:4539-48.
41. Galderisi, U., Cipollaro, M. and Giordano, A. 2006. The retinoblastoma gene is involved in multiple aspects of stem cell biology. Oncogene, 25:5250-6.
42. Gamble, S.C., Chotai, D., Odontiadis, M., Dart, D.A., Brooke, G.N., Powell, S.M., Reebye, V., Varela-Carver, A., Kawano, Y., Waxman, J. and Bevan, C.L. 2007. Prohibitin, a protein downregulated by androgens, represses androgen receptor activity. Oncogene, 26:1757-68.
43. Gamble, S.C., Odontiadis, M., Waxman, J., Westbrook J.A., Dunn, M.J., Wait, R., Lam, E.W. and Bevan, C.L. 2004. Androgens target prohibitin to regulate proliferation of prostate cancer cells. Oncogene, 23:2996-3004.
44. Giacinti, C. and Giordano, A. 2006. RB and cell cycle progression. Oncogene, 25:5220-7.
45. Gladden, A.B. and Diehl, J.A. 2005. Location, location, location: the role of cyclin D1 nuclear localization in cancer. J. Cell. Biochem., 96:906-13.
46. Gradishar, W.J. 2004. Tamoxifen - what next? Oncologist, 9:378-84.
47. Graef, M., Seewald, G. and Langer, T. 2007. Substrate recognition byAAA+ATPases: distinct substrate binding modes in ATP-dependent protease Yme1 of the mitochondrial intermembrane space. Mol. Cell. Biol., 27:2476-85.
48. Halaban, R. 2005. Rb/E2F: a two-edged sword in the melanocytic system. Cancer Metastasis Rev., 24:339-56.
49. Harbour, J.W. and Dean, D.C. 2000. Rb function in cell-cycle regulation and apoptosis. Nat. Cell. Biol., 2:E65-7.
50. Harris, S. L. and Levine, A.J. 2005. The p53 pathway: positive and negative feedback loops. Oncogene, 24:2899-908.
51. Heron-Milhavet, L., Mamaeva, D., Rochat, A., Lamb, N.J. and Fernandez, A. 2007. Akt2 is implicated in skeletal muscle differentiation and specifically binds Prohibitin2/REA. J. Cell. Physiol.,
52. Howell, A., Cuzick, J., Baum, M., Buzdar, A., Dowsett, M., Forbes, J.F., Hoctin-Boes, G., Houghton, J., Locker, G.Y. and Tobias, J. S. 2005. Results of the ATAC (Arimidex, Tamoxifen. Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet, 365:60-2.
53. Huang, C.Y., Beliakoff, J., Li, X., Lee, J., Li, X., Sharma, M., Lim, B. and Sun, Z. 2005. hZimp7, a novel PIAS-like protein, enhances androgen receptor-mediated transcription and interacts with SWI/SNF-like BAF complexes. Mol. Endocrinol., 19:2915-29.
54. Hussain-Hakimjee, E.A., Peng, X., Mehta, R.R. and Mehta, R.G. 2006. Growth inhibition of carcinogen-transformed MCF-12F breast epithelial cells and hormone-sensitive BT-474 breast cancer cells by 1alpha-hydroxyvitamin D5. Carcinogenesis, 27:551-9.
55. Hussain, S.A., Palmer, D.H., Moon, S. and Rea, D.W. 2004. Endocrine therapy and other targeted therapies for metastatic breast cancer. Expert Rev. Anticancer Ther., 4:1179-95.
56. Illing, R. and Chapman, A. 2007. The clinical applications of high intensity focused ultrasound in the prostate. Int. J. Hyperthermia, 23:183-91.
57. Inayoshi, Y., Miyake, K., Machida, Y., Kaneoka, H., Terajima, M., Dohda, T., Takahashi, M. and Iijima, S. 2006. Mammalian Chromatin Remodeling Complex SWI/SNF Is Essential for Enhanced Expression of the Albumin Gene during Liver Development. J. Biochem. (Tokyo), 139:177-88.
58. Johnson, D.G. and Schneider-Broussard, R. 1998. Role of E2F in cell cycle control and cancer. Front Biosci., 3:d447-8.
59. Joshi, B., Rastogi, S., Morris, M., Carastro, L.M., DeCook, C., Seto, E. and Chellappan, S.P. 2007. Differential regulation of human YY1 and caspase 7 promoters by prohibitin through E2F1 and p53 binding sites. Biochem. J., 401:155-66.
60. Kang, H., Cui, K. and Zhao, K. 2004. BRG1 controls the activity of the retinoblastoma protein via regulation of p2lCIP1/WAF1/SDI. Mol. Cell. Biol., 24:1188-99.
61. Khidr, L. and Chen, P.L. 2006. RB, the conductor that orchestrates life, death and differentiation. Oncogene, 25:5210-9.
62. Korenjak, M. and Brehm, A. 2005. E2F-Rb complexes regulating transcription of genes important for differentiation and development. Curr. Opin. Genet. Dev., 15:520-7.
63. Korenjak, M. and Brehan, A. 2006. The retinoblastoma tumour suppressor in model organisms - new insights from flies and worms. Curr. Mol. Med.,6:705-11.
64. Kurebayashi, J. 2003. Endocrine-resistant breast cancer: underlying mechanisms and strategies for overcoming resistance. Breast Cancer, 10:112-9.
65. Kurtev, V., Margueron, R., Kroboth, K., Ogris, E., Cavailles, V. and Seiser, C. 2004. Transcriptional regulation by the repressor of estrogen receptor activity via recruitment of histone deacetylases. J. Biol. Chem., 279:24834-43.
66. Lauth, M. and Toftgard, R. 2007. The Hedgehog pathway as a drug target in cancer therapy. Curr Opin. Investig. Drugs, 8:457-61.
67. Lee, C.H., Murphy, M.R., Lee, J.S. and Chung, J.H. 1999. Targeting a SWI/ SNF-related chromatin remodeling complex to the beta-globin promoter in erythroid cells. Proc. Natl. Acad. Sci. U.S.A., 96:12311-5.
68. Letimier, F.A., Passini, N., Gasparian, S., Bianchi, E. and Rogge, L. 2007. Chromatin remodeling by the SWI/SNF-like BAF complex and STAT4 activation synergistically induce IL-12Rbeta2 expression during human Th1 cell differentiation. Embo J., 26:1292-1302.
69. Li, L.C. 2007. Epigenetics of prostate cancer. Front Biosci., 12:3377-97.
70. Lickert, H., Takeuchi, J.K., Von Both, I., Walls, J.R., McAuliffe, F., Adamson, S.L., Henkelman, R.M., Wrana, J.L., Rossant, J. and Bruneau, B.G. 2004. Baf60c is essential for function of BAF chromatin remodelling complexes in heart development. Nature, 432:107-12.
71. Lofgren, L., von Schoultz, E., Fernstad, R., von Schoultz, B. and Carlstrom, K. 2006. Are estrogen receptor content in breast cancer and effects of tamoxifen on sex hormone-binding globulin markers for individual estrogen sensitivity? J Steroid Biochem. Mol. Biol., 99:76-9.
72. Lukka, H., Waldron, T., Klotz, L., Winquist, E. and Trachtenberg, J. 2006. Maximal androgen blockade for the treatment of metastatic prostate cancer-a systematic review. Curr. Oncol., 13:81-93.
73. Macleod, K. 1999. pRb and E2f-1 in mouse development and tumorigenesis. Curr. Opin. Genet. Dev., 9:31-9.
74. Mandlekar, S. and Kong, A.N. 2001. Mechanisms of tamoxifen-induced apoptosis. Apoptosis, 6:469-77.
75. Margutti, S. and Laufer, S.A. 2007. Are MAP Kinases Drug Targets? Yes, but Difficult Ones. Chem. Med. Chem.,
76. McClung, J.K., Jupe, E.R., Liu, X.T. and Dell'Orco, R.T. 1995. Prohibitin: potential role in senescence, development; and tumor suppression. Exp. Gerontol., 30:99-124.
77. McClung, J.K., King, R.L., Walker, L.S., Danner, D.B., Nuell, M.J., Stewart, C.A. and Dell'Orco, R.T. 1992. Expression of prohibitin, an antiproliferative protein. Exp. Gerontol., 27:413-7.
78. Mishra, S., Murphy, L.C. and Murphy, L.J. 2006. The Prohibitins: emerging roles in diverse firactions. J. Cell. Mol. Med., 10:353-63.
79. Mishra, S., Murphy, L.C., Nyomba, B.L. and Murphy, L.J. 2005. Prohibitin: a potential target for new therapeutics. Trends Mol. Med., 11:192-7.
80. Montano, M.M., Ekena, K., Delage-Mourroux, R., Chang, W., Martini, P. and Katzenellenbogen, B.S. 1999. An estrogen receptor-selective coregulator that potentiates the effectiveness of antiestrogens and represses the activity of estrogens. Proc. Natl. Acad. Sci. U.S.A., 96:6947-52.
81. Morrow, I.C., Rea, S., Martin, S., Prior, I.A., Prohaska, R., Hancock, J.F., James, D.E. and Parton, R.G. 2002. Flotillin-1/reggie-2 traffics to surface raft domains via a novel golgi-independent pathway. Identification of a novel membrane targeting domain and a role for palmitoylation. J. Biol. Chem., 277:48834-41.
82. Mousavi, S.R. and Rezaci, M. 2006. Tamoxifen effects on treatment fibrocystic breast disease in women. Saudi Med. J., 27:565-6.
83. Msaouel, P., Diamanti, E., Tzanela, M. and Koutsilieris, M. 2007. Luteinising hormone-releasing hormone antagonists in prostate cancer therapy. Expert Opin. Emerg. Drugs, 12:285-99.
84. Muller, H. and Helin, K. 2000. The E2F transcription factors: key regulators of cell proliferation. Biochim. Biophys. Acta., 1470:M1-12.
85. Murphy, L.C., Simon, S.L., Parkes, A., Leygue, E., Dotzlaw, H., Snell, L., Troup, S., Adeyinka, A. and Watson, P.H. 2000. Altered expression of estrogen receptor coregulators during human breast tumorigenesis. Cancer Res., 60:6266-71.
86. Mussi, P., Liao, L., Park, S.E., Ciana, P., Maggi, A., Katzenellenbogen, B.S., Xu, J. and O'Malley, B.W. 2006. Haploinsufficiency of the corepressor of estrogen receptor activity (REA) enhances estrogen receptor function in the mammary gland. Proc. Natl. Acad. Sci. U.S.A., 103:16716-21.
87. Narayanan, B.A. 2006. Chemopreventive agents alters global gene expression pattern: predicting their mode of action and targets. Curr. Cancer Drug Targets, 6:711-27.
88. Nevins, J.R. 2001. The Rb/E2F pathway and cancer. Hum. Mol. Genet., 10:699-703.
89. Nevins, J.R., Leone, G., DeGregori, J. and Jakoi, L. 1997. Role of the Rb/E2F pathway in cell growth control. J. Cell. Physiol., 173:233-6.
90. Nuell, M.J., Stewart, D.A., Walker, L., Friedman, V., Wood, C.M., Owens, G.A., Smith, J.R., Schneider, E.L., Dell' Orco, R. and Lumpkin, C.K. et al. 1991. Prohibitin, an evolutionarily conserved intracellular protein that blocks DNA synthesis in normal fibroblasts and HeLa cells. Mol. Cell. Biol., 11: 1372-81.
91. O'Connor, J.C., Farach-Carson, M.C., Schneider, C.J. and Carson, D.D. 2007. Coculture with prostate cancer cells alters endoglin expression and attenuates transforming growth factor-beta signaling in reactive bone-marrow stromal cells. Mol. Cancer Res., 5:585-603.
92. O'Regan, R.M. 2006. Chemoprevention of breast cancer. Lancet, 367:1382-3.
93. Osborne, C.K., Shou, J., Massarweh, S. and Schiff, R. 2005. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin. Cancer Res., 11:865s-70s.
94. Osman, C., Wilmes, C., Tatsuta, T. and Langer, T. 2007. Prohibitins interact genetically with Atp23, a novel processing peptidase and chaperone for the F1Fo-ATP synthase. Mol. Biol. Cell., 18:627-35.
95. Park,S.E., Xu, J., Frolova, A., Liao, L., O'Malley, B.W. and Katzenelienbogen, B.S. 2005. Genetic deletion of the repressor of estrogen receptor activity (REA) enhances the response to estrogen in target tissues in vivo. Mol. Cell. Biol., 25:1989-99.
96. Peng, X., Mehta, R., Wang, S., Chellappan, S. and Mehta, R.G. 2006. Prohibitin is a novel target gene of vitamin D involved in its antiproliferative action in breast cancer cells. Cancer Res., 66:7361-9.
97. Peng, X. and Mehta, R.G. 2007. Differential expression of prohibitin is correlated with dual action of Vitamin D as a proliferative and antiproliferative hormone in breast epithelial cells. J. Steroid Biochem. Mol. Biol., 103:446-50.
98. Qin, X.Q., Livingston, D.M., Ewen, M., Sellers, W.R., Arany, Z. and Kaelin, W.G. 1995. The transcription factor E2F-1 is a downstream target of RB action. Mol. Cell. Biol., 15:742-55.
99. Rabenoelina, F., Semlali, A., Duchesne, M.J., Freiss, G., Pons, M. and Badia, E. 2002. Effect of prolonged hydroxytamoxifen treatment of MCF-7 cells on mitogen activated kinase cascade. Int. J. Cancer, 98:698-706.
100. Rajalingam, K. and Rudel, T. 2005. Ras-Raf signaling needs prohibitin. Cell. Cycle, 4:1503-5.
101. Rajalingam, K., Wunder, C., Brinkmann, V., Churin, Y., Hekman, M., Sievers, C., Rapp, U.R. and Rudel, T. 2005. Prohibitin is required for Ras-induced Raf-MEK-ERK activation and epithelial cell migration. Nat. Cell. Biol., 7:837-43.
102. Rando, O.J., Zhao, K., Janmey, P. and Crabtree, G.R. 2002. Phosphatidylinositol-dependent actin filament binding by the SWI/ SNF-like BAF chromatin remodeling complex. Proc. Natl. Acad. Sci. U.S.A., 99:2824-9.
103. Rasmussen, R.K., Ji, H., Eddes, J.S., Moritz, R.L., Reid, G.E., Simpson, R.J. and Dorow, D.S. 1998. Two-dimensional electrophoretic analysis of mixed lineage kinase 2 N-terminal domain binding proteins. Electrophoresis, 19:809-17.
104. Rastogi, S., Joshi, B., Dasgupta, P., Morris, M., Wright, K. and Chellappan, S. 2006a. Prohibitin facilitates cellular senescence by recruiting specific corepressors to inhibit E2F target genes. Mol. Cell. Biol., 26:4161-71.
105. Rastogi, S., Joshi, B, Fusaro, G. and Chellappan, S, 2006b. Camptothecin induces nuclear export of prohibitin preferentially in transformed cells through a CRM-1-dependent niechanism. J. Biol. Chem., 281:2951-9.
106. Roberts, P.J. and Der, C.J. 2007. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene, 26:3291-310.
107. Robertson, J.F., Come, S.E., Jones, S.E., Beex, L., Kaufmann, M., Makris, A., Nortier, J.W., Possinger, K. and Rutqvist, L.E. 2005. Endocrine treatment options for advanced breast cancer - the role of fulvestrant. Eur. J. Cancer, 41:346-56.
108. Rogoff, H.A. and Kowalik, T.F. 2004. Life, death and E2F: linking proliferation control and DNA damage signaling via E2F1. Cell. Cycle, 3:845-6.
109. Rubenstein, M., Tsui, P. and Guinan, P. 2006. Bispecific antisense oligonucleotides with multiple binding sites for the treatment of prostate tumors and their applicability to combination therapy. Methods Find Exp. Clin. Pharmacol., 28:515-8.
110. Ruiz, S., Santos, M. and Paramio, J.M. 2006. Is the loss of pRb essential for the mouse skin carcinogenesis? Cell. Cycle, 5:625-9.
111. Ryan, C.J. and Beer, T.M. 2007. Prostate Specific Antigen Only Androgen Independent Prostate Cancer: Natural History, Challenges in Management and Clinical Trial Design. J. Urol.,
112. Saeki, T., Tsuruo, T., Sato, W. and Nishikawsa, K. 2005. Drug resistance in chemotherapy for breast cancer. Cancer Chemother. Pharmacol., 56(Suppl 1):84-9.
113. Sampson, N., Untergasser, G., Lilg, C., Tadic, L., Plas, E. and Berger, P. 2007. GAGEC1, a cancer/testis associated antigen family member, is a target of TGF-betal in age-related prostatic disease. Mech. Ageing Dev., 128:64-6.
114. Sato, T., Saito, H., Swensen, J., Olifant, A., Wood, C., Danner, D., Sakamoto, T., Takita, K., Kasumi, F. and Miki, Y. et al. 1992. The human prohibitin gene located on chromosome 17q21 is mutated in sporadic breast cancer. Cancer Res., 52:1643-6.
115. Sato, T., Sakamoto, T., Takita, K., Saito, H., Okui, K. and Nakamura, Y. 1993. The human prohibitin (PHB) gene family and its somatic mutations inhuman tumors. Genomics, 17:762-4.
116. Schiff, R., Massarweh, S., Shou, J. and Osborne, C.K. 2003. Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clin. Cancer Res., 9:447S-54S.
117. Sebastian, T. and Johnson, P.F 2006. Stop and go: anti-proliferative and mitogenic functions of the transcription factor C/EBPbeta. Cell. Cycle, 5:953-7.
118. Sellers, W.R. and Kaelin, W.G. 1997. Role of the retinoblastoma protein in the pathogenesis of human cancer. J. Clin. Oncol., 15:3301-12.
119. Sharifi, N., Hurt, E.M., Kawasaki, B.T. and Farrar, W.L. 2007. TGFBR3 loss and consequences in prostate cancer. Prostate, 67:301-11.
120. Shidaifat, F., Al-Trad, B. and Al-Omari, R. 2007a. Testosterone effect on immature prostate gland development associated with suppression of transforming growth factor-beta. Life Sci., 80:829-34.
121. Shidaifat, F., Gharaibeh, M. and Bani-Ismail, Z. 2007b. Effect of Castration on Extracellular Matrix Remodeling and Angiogenesis of the Prostate Gland. Endocr J.,
122. Shrivastava, V., Christenson, R. and Poggi, M.M. 2007. Prostate cancer metastatic to the external auditory canals. Clin. Genitourin. Cancer, 5:341-3.
123. Signorelli, P. and Ghidoni, R. 2005. Resveratrol as an anticancer nutrient: molecular basis, open questions and promises. J. Nutr. Biochem., 16:449-66.
124. Simon, S.L., Parkes, A., Leygue, E., Dotzlaw, H., Snell, L., Troup, S., Adeyinka, A., Watson, P.H. and Murphy, L.C. 2000. Expression of a repressor of estrogen receptor activity in human breast tumors: relationship to some known prognostic markers. Cancer Res., 60:2796-9.
125. Stanelle, J. and Putzer, B.M. 2006. E2F1 -induced apoptosis: turning killers into therapeutics. Trends Mol. Med., 12:177-85.
126. Steglich, G., Neupert, W. and Langer, T. 1999. Prohibitins regulate membrane protein degradation by the m-AAA protease in mitochondria. Mol. Cell. Biol., 19:3435-42.
127. Sugimoto, T., Dazai, K., Sakashita, T., Funayama, T., Wada, S., Hamada, N., Kakizaki, T., Kobayashi, Y. and Higashitani, A. 2006. Cell. cycle arrest and apoptosis in Caenorhabditis elegans germline cells following heavy-ion microbeam irradiation. Int. J. Radiat. Biol., 82:31-8.
128. Suh, S.K., Hood, B.L., Kim, B.J., Conrads, T.P., Veenstra, T.D. and Song, B.J. 2004. Identification of oxidized mitochondrial proteins in alcohol-exposed human hepatoma cells and mouse liver. Proteomics, 4:3401-12.
129. Takeuchi, J.K., Lickert, H., Bisgrove, B.W., Sun, X., Yamamoto, M., Chawengsaksophak, K., Hamada, H., Yost, H.J., Rossant, J. and Bruneau, B.G. 2007. Baf60c is a nuclear Notch signaling component required for the establishment of left-right asymmetry. Proc. Natl. Acad Sci. U.S.A., 104:846-51.
130. Terashima, M., Kim, K.M., Adachi, T., Nielsen, P.J., Reth, M., Kohler,,G. and Lamers, M.C. 1994. The IgM antigen receptor of B. lymphocytes is associated with prohibitin and a prohibitin-related protein. Embo. J., 13:3782-92.
131. Trotter, K.W. and Archer, T.K. 2004. Reconstitution of glucocorticoid receptor-dependent trascription in vivo. Mol. Cell. Biol., 24:3347-58.
132. Tsai, M.H., Cook, J.A., Chandramouli, G.V., DeGraff, W., Yan,H., Zhao, S., Coleman, C.N., Mitchell, J.B. and Chuang, E.Y. 2007. Gene expression profiling of breast, prostate, and glioma cells following single versus fractionated doses of radiation. Cancer Res., 67:3845-52.
133. Turley, R.S., Finger, E.C., Hempel, N., How, T., Fields, T.A. and Blobe, G.C. 2007. The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer. Cancer Res., 67:1090-98.
134. Uchida, K., Kanai, M., Yonemura, S., Ishii, K., Hirokawa, Y. and Sugimura, Y. 2007. Proprotein convertases modulate budding and branching morphogeresis of rat ventral prostate. Int. J. Dev. Biol., 51:229-33.
135. Underhill, C., Qutob, M.S., Yee, S.P. and Torchia, J. 2000. A novel nuclear receptor corepressor complex, N-CoR, contains components of the mammalian SWI/SNF complex and the corepressor KAP-1. J. Biol. Chem., 275:40463-70.
136. Wang, F.L., Qin, W.J., Wen, W.H., Tian, F., Song, B., Zhang, Q., Lee, C., Zhong, W.D., Guo, Y.L. and Wang, H. 2007. TGP-beta insensitive dendritic cells: an efficient vaccine for murine prostate concer. Cancer Immunol. Immunother.,
137. Wang, S., Fusaro, G., Padmanabhan, J. and Chellappan, S.P. 2002a. Prohibitin co-localizes-with Rb in the nucleus and recruits N-CoR and HDAC1 for transcriptional repression. Oncogene, 21:8388-96.
138. Wang, S., Ghosh, R.N. and Chellappan, S.P. 1998. Raf-1 physically interacts with Rb and regulates its function: a link between mitogenic signaling and cell cycle regulation. Mol. Cell. Biol., 18:7487-98.
139. Wang, S., Nath, N., Adlam, M. and Chellappan, S. 1999a. Prohibitin, a potential tumor suppressor, interacts with RB and regulates E2F function. Oncogene, 18:3501-10.
140. Wang, S., Nath, N., Fusaro, G. and Chellappan, S. 1999b. Rb and prohibitin target distinct regions of E2171 for repression and respond to different upstream signals. Mol. Cell. Biol., 19:7447-60.
141. Wang, S., Nath, N., Minden, A. and Chellappan, S. 1999c. Regulation of Rb and E2F by signal transduction cascades: divergent effects of JNK1 and p38 kinases. Embo J., 18:1559-70.
142. Wang, S., Zhang, B. and Faller, D.V. 2002b. Prohibitin requires Brg-1 and Brm for the repression of E2F and cell growth. Embo J., 21:3019-28.
143. Wang, S., Zhang, B. and Faller, D.V. 2004. BRG1/BRM and prohibitin are required for growth suppression by estrogen antagonists. Embo J., 23:2293-303.
144. Wang, W., Cote, J., Xue, Y., Zhou, S., Khavari, P.A., Biggar, S.R., Muchardt, C., Kalpana, G.V., Goff, S.P., Yaniv, M., Workman, J.L. and Crabtree, G.R. 1996. Purification and biochemical heterogeneity of the mammalian SWI-SNF complex. Embo J., 15:5370-82.
145. White, J.J., Ledbetter, D.H., Eddy, R.L.Jr, Shows, T.B., Stewart D.A., Nuell, M.J., Friedman, V., Wood, C.M., Owens, G.A., McClung, J.K. et al. 1991. Assignment of the human prohibitin gene (PHB) to chromosome 17 and identification of a DNA polymorphism. Genomics, 11:228-30.
146. Yamasaki, L. 2003. Role of the RB tumor suppressor in cancer. Cancer Treat Res., 115:209-39.
147. Yang, F., Strand, D.W. and Rowley, D.R. 2007. Fibroblast growth factor-2 mediates transforming growth factor-beta action in prostate cancer reactive stroma. Oncogene.
148. Ye, L., Lewis-Russell, J.M., Davies, G., Sanders, A.J., Kynaston, H. and Jiang, W.G. 2007a. Hepatocyte growth factor up-regulates the expression of the bone morphogenetic protein (BMP) receptors, BMPR-IB; and BMPR-II, in human prostate cancer cells. Int. J. Oncol., 30:521-9.
149. Ye, L., Lewis-Russell, J.M., Kyanaston, H.G. and Jiang, W.G. 2007b. Bone morphogenetic proteins and their receptor signaling in prostate cancer. Histol. Histopathol., 22:1129-47.
150. Yee, E.F., White, R.E., Murata, G.H., Handanos, C. and Hoffman, R.M. 2007. Osteoporosis Management in Prostate Cancer Patients Treated with Androgen Deprivation Therapy. J. Gen. Intern. Med.,
151. Zhang, B., Chambers, K.J., Faller, D.V. and Wang, S. 2007. Reprogramming of the SWI/SNF complex for co-activation or co-repression in prohibitin-mediated estrogen receptor regulation. Oncogene,
152. Zhao, K., Wang, W., Rando, O.J., Xue, Y, Swiderek, K., Kuo, A. and Crabtree, G.R. 1998. Rapid and phosphoinositol-dependent binding of the SWI/SNF-like BAF complex to chromatin after T lymphocyte receptor signaling. Cell., 95:625-36.
153. Zhao, L.H., Ba, X.Q., Wang, X.G., Zhu, X.J., Wang, L. and Zeng, X.L. 2005. BAF complex is closely related to and interacts with NF1/CTF and RNA polymerase 11 in gene transcriptional activation. Acta. Biochim. Biophys. Sin. (Shanghai), 37:440-6.
154. Zhu, B., Fukada, K., Zhu, H. and Kyprianou, N. 2006. Prohibitin and Cofilin Are Intracellular Effectors of Transforming Growth Factor {beta} Signaling in Human Prostate Cancer Cells. Cancer Res., 66:8640-7.
155. Zhu, L. 2005. Tumour suppressor retinoblastoma protein Rb: a transcriptional regulator. Eur. J. Cancer, 41:2415-27.